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Bronchial methacholine challenge is well established in asthma diagnostics and research. ATS
guidelines propose a five step standard dosimeter (SDM) protocol with incremental concentra-
tions of methacholine to calculate the concentration causing a 20% drop in FEV1 in an individual
(PC20FEV1). In contrast, the aerosol provocation system (APS) by Viasys
 automatically deter-
mines the administered dose of methacholine by measuring the effective nebulisation time
and referring it to drug concentration and nebuliser power. Therefore, it offers a feasible
and less time-consuming provocation procedure by applying incremental doses (PD20) of
methacholine using a single concentration (16 mg/mL methacholine, APS-SC). In this study
we compared these two methods in 52 young adults (25 5.8 years). Following a screening
visit, subjects were randomly assigned to undergo either SDM or APS-SC followed by the other
method within 1 week. A close correlation between concentration and dosage causing a 20%
fall of FEV1 was found (rZ 0.69, p< 0.001).
Using the ATS categorisation of bronchial responsiveness we interpreted the results of the APS-
SCmethod as follows: PD20methacholine< 0.3 mg as ‘‘moderate to severe BHR’’, 0.3e 0.6 mg as
‘‘mild BHR’’, 0.6 e 1.0 mg as ‘‘borderline BHR’’, and> 1.0 mg as ‘‘normal bronchial response’’.
We conclude that the five-step APS-SC is a suitable method, providing reliable results. In clin-
ical practice the APS-SC is a timesaving procedure and less prone to errors since only one dilution
of methacholine is necessary compared to the SDM.
ª 2009 Elsevier Ltd. All rights reserved.reactivity; MCT, methacholine challenge testing; ATS, American Thoracic Society; APS, aerosol
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Age [yr] 25 5.8
Weight [kg] 67.3 14.3
Height [cm] 174.1 9.5
FEV1 [% predicted] 102.7 13.0
VC [% predicted] 97.9 13.4
Data are presented as mean SD unless otherwise indicated.Methacholine challenge testing (MCT) is a well established
method of assessing airway responsiveness. The most
common clinical indication is to evaluate the likelihood of
asthma in patients in whom the diagnosis is suggested by
current symptoms but is not obvious.1 American Thoracic
Society (ATS) guidelines1 suggest two dosing protocols: the
2-min tidal breathing method,2 and the five-breath dosim-
eter method.3 The five-breath dosimeter protocol consists
of fewer dilution steps and is therefore more suitable. Both
methods have some inherent pitfalls. These include errors
in dilution and inaccurate delivery if equipment is not
calibrated.4 Categorisation of bronchial responsiveness
PC20 is suggested as follows (PC20 FEV1, mg/mL): 16 normal
bronchial responsiveness, 4.0e16 borderline BHR, 1.0e4.0
mild BHR (positive test), and 1.0 moderate to severe BHR.1
The interpretation of results is not consistent as a positive
test is often defined as a PC20< 8 or< 16 mg/ml.
1 ATS
guidelines recommend the use of an intermediate area of
‘‘borderline BHR’’ to improve the specificity of MCT. A
negative methacholine challenge result is commonly
defined as non-response to the highest concentration
(PC20> 8e25 mg/ml). False-negative methacholine chal-
lenges occur much less frequently than false-positive
results.1 Cockcroft et al. found in a random selection of
young students in subjects with current symptomatic
asthma a negative predictive value of 100% and a positive
predictive value of only 29%.5
The aerosol provocation system (APS, Viasys healthcare)
is a flow-controlled nebuliser system which performs
reproducible provocation tests and ensures accurate
dosage. With each inspiration the patient inhales a specific
dose of the applied substance, e.g., methacholine. In
contrast to methods with different concentrations, the APS
delivers incremental doses of methacholine using
a constant concentration. The advantages are prevention
of dilution errors and saving the time for preparing the
dilutions. Between the different steps the dilution doesn’t
need to be replaced. Thus, the APS is user-friendly and
suitable for everyday clinical practice, particularly in
combination with a short-protocol.
Despite a widespread distribution of the APS, solid data
about interpretation of results of MCT with this system is
rare.7,8 This study compares two short protocols namely the
five-breath dosimeter method and a short-protocol using
the APS. We provide an assessment of the categories using




Fifty five subjects aged 14e45 years with known BHR, who
participated already in former studies, were recruited.
Following the first visit they were randomised to one of the
two methods. Subjects’ baseline characteristics are sum-
marised in Table 1. Subjects were excluded if they had
a therapy with inhaled or oral corticosteroids, long acting
beta-agonists or leukotriene receptor antagonists. Thestudy was approved by the Ethics Committee of the
Goethe-university, written informed consent was obtained
in advance from each subject (in minors additionally from
the parents).
Study design
This was an unblinded, randomised, crossover study con-
sisting of two visits. Each visit was at least 48 hours but not
more than 7 days apart. Participants attended an initial
visit to assess baseline characteristics and lung function.
After that, participants were randomised to one of the two
methacholine challenge methods by using a random list. On
the same visit the first challenge was performed. Primary
endpoint was the concentration or dose causing a 20% drop
in FEV1 from baseline. During the provocation oxygen
saturation and heart rate were monitored. The duration of
each test was documented. After the challenge the
participants received one to three puffs of Salbutamol
(0.2 mg) until the FEV1 returned to at least 80% of the
baseline value. On the second visit the other methacholine
challenge protocol was performed.
Test products
Methacholine chloride solutions were prepared from
a commercial powder (Fagron Ltd., Barsbu¨ttel, Germany)
by a clinical pharmacist. A stock solution of 16 mg/mL
metchacholine in 50 ml 0.9% saline (pH 4.8) was made. The
solution was stored at 4 C up to three months. For the five-
breath dosimeter method, different dilutions containing
0.0625 mg/mL, 0.25 mg/mL, 1.0 mg/mL, 4.0 mg/mL, and
16.0 mg/mL were prepared.
Standard dosimeter method (SDM)
The dosimeter method was performed according to Amer-
ican Thoracic Society guidelines using the above mentioned
concentrations.1 The methacholine dilutions were deliv-
ered through a mouthpiece attached to a DeVilbiss 646
nebuliser (DeVilbiss Co., Sommerset, USA) driven by
a ZAN200 ProvAir II ultrasound dosimeter (nSpire Health
Ltd, Oberthulba, Germany). The ZAN200 ProvAir II was
calibrated to produce an output of 0.009 mL per 0.6-s
actuation. Particle size was 5 mm. During tidal breathing
(functional residual capacity) the subject was instructed to
inhale slowly and deeply from the nebuliser. Soon after the
inhalation began the dosimeter was triggered. Participants
1900 J. Schulze et al.were encouraged to inhale slowly and deeply over 5 s to
total lung capacity and to hold the breath for another 5 s.
This was repeated for a total of five inhalations. 120 s after
each step FEV1 was measured. PC20FEV1 was calculated by
logarithmic interpolation.9 Before and after each inhalation
step the nebuliser was weighed using a balance (Kern 440-
21A) accurate to 0.001 g, and inhaled doses of methacho-
line were calculated.
Single concentration method using the Aerosol
Provocation System (APS-SC)
The APS dosimeter technique (VIASYS Healthcare GmbH)
allows computer controlled production of aerosol, using
a jet-type nebuliser (Sidestream, Medic Aid) powered by
compressed air. Integrated calibration procedures ensure
highly constant and reproducible nebuliser output. Major
advantages of this system are real-time visualisation of
dose administration and breathing pattern.
The system exactly and automatically determines the
administered dose of methacholine by measuring the
effective nebulisation time at inspiration of any breath and
referring it to drug concentration and nebuliser power.
Subjects were instructed to inhale slowly and deeply
from the nebuliser with maximal flows below 0.5 L/s. APS
was calibrated to produce an output of 160 mg/min,
particle size was 3.2 mm. The doses of inhaled methacho-
line with a concentration of 16 mg/mL were increased
according to the following pattern, from step 1 to 5: 0.01,
0.1, 0.4, 0.8, and 1.6 mg. Thus, the entire protocol deliv-
ered cumulative doses of 0.01, 0.11, 0.51, 1.31 and 2.91 mg
(Table 2). Two minutes after each inhalation, FEV1 was
measured, and PD20 FEV1 was calculated by logarithmic
interpolation9 using an integrated program.
Statistical analysis
For statistical analysis BiAS for Windows (Version 8,
epsilon-publisher, Frankfurt, Germany) was used. Rela-
tionship between the two methods was examined by
determining the Pearson correlation coefficient. Cut-points
of APS-SC were primarily defined by using Hahn-prognosis
intervals, which is based on a regression analysis. Hahn-
prognosis estimates the variability of corresponding resid-
uals to a given value, e.g., the variability of expected PD20
to a given PC20. For these cut-points inter-rater agreement
was measured using Cohen’s kappa coefficient.Table 2 Steps and methacholine concentrations during
bronchial provocation using the APS-SC.






5 1.60 2.91To assess the significance of the difference between both
methods McNemar’s test was used. If marginal frequencies,
e.g. subjectswho react only to one of bothmethods, in a 2 2
classification table are not homogeneous, McNemar is signifi-
cant (p> 0.05). Differences between both methods were
measured with student’s t-test.Results
Subject characteristics
In total, 31 female and 21 male subjects aged 14e45 years
completed the study. One participant started a therapy with
inhaled corticosteroids between the visits andwas excluded.
Two participants didn’t appear for the second provocation
and were excluded. All subjects (nZ 52) had baseline FEV1
values of> 80% predicted and baseline FEV1 was similar for
both methods (SDM FEV1 102%, SD 13.4%, APS-SC 103%, SD
13.7%, pZ 0.33), as well as the maximal post-challenge fall
of FEV1 (SDM FEV1 25.6%, SD 12.7%, APS-SC 28.7%, SD 10.8%,
pZ 0.08). For FEV1 and FVC manoeuvres, ATS/ERS test
criteria for acceptability and repeatabilityweremet in 87.3%
of all measurements.10 All participants performed adequate
MCTs. Of these, six were nonresponsive neither to the SDM
nor to the APS-SC method. Eight were nonresponsive to the
SDM but had a positive PD20FEV1 to APS-SC, and two were
nonresponsive to APS-SC but had a positive PC20FEV1 to SDM.
All subjectswere included in the calculations. For those,who
were nonresponsive to any of the methods, maximum
concentration ordose, 16 mg/mLor 2.91 mgofmethacholine
respectively, were assumed (Fig. 1 A).Comparison of the two methods
Pearson correlation for the two methods was rZ 0.69
(p< 0.001) (Fig. 1 A). Using Hahn-prognosis test we calcu-
lated the corresponding thresholds for different categories
of BHR according to ATS-guidelines1 (Fig. 1 B). A concen-
tration of 8 mg/mL methacholine was considered as the
usually accepted cut-point of BHR. Moderate to severe BHR
would correspond with a PD20 methacholine< 0.3 mg, mild
with 0.3e0.6 mg, borderline with 0.6e1.0 mg, and normal
bronchial response> 1.0 mg. Moreover, thresholds were
calculated using only subjects with data within the range
(nZ 36). Results were similar to the data involving all
subjects (rZ 0.54, p< 0.001). The association between
tests was confirmed calculating the PD20 cut-points with the
highest kappa statistic for each PC20 (Table 3). All cut-
points showed significant agreements. At the 8 mg/mL
cut-point both methods would detect 27 of 52 (52%)
subjects with BHR and exclude 16 of 52 (31%). Thus, the
overall agreement was 83% (McNemar, pZ 0.51) (Table 4).
For those subjects who had a positive reaction within
the range (nZ 36), we measured the inhaled metha-
choline doses and length of time at the point of PC20FEV1
and PD20 FEV1. Mean dose for SDM was 0.89 mg (SD 0.84)
methacholine, and for APS-SC 0.51 mg (SD 0.50) metha-
choline (p< 0.005). Mean duration of SDM was 23.4 min
(SD 6.08) and of APS-SC 15.3 min (SD 6.04) (p< 0.001),
respectively.
Table 4 Distribution of positive and negative results
comparing dosimeter and APS method.
PD20 S
<1.0 mg 1.0 mg
PC20 <8.0 mgmL
1 27 3 30
8.0 mgmL1 6 16 22
S 33 19 52
McNemar test (pZ 0.51).
Fig. 1 Distribution of provocative concentration of methacholine versus provocative dose of methacholine causing a 20% fall of
FEV1. (A) The regression was calculated using all subjects (n = 52) including those 16 outside the range of 16 mg/mL and 2.91 mg
methacholine, respectively (r = 0.69). (B) Hahn 95 % prognosis interval. The bold line shows the regression, whereas the outer lines
represent the band of expected PD20 values corresponding to a given PC20 value.
Table 3 Comparison between optimum cut-points for agreement between the dosimeter and APS method.
PC20- cut point [mg/mL] PD20- cut point [mg] D PD20 Agreement [%] Cohen’s kappa (linear) p-value (of kappa)
1.0 0.3 0.1 76.9 0.46 < 0.005
2.0 0.4 0.2 76.9 0.43 < 0.005
4.0 0.6 0.4 78.9 0.54 <0.001
8.0 1.0 0.9 82.7 0.59 <0.001
16.0 1.9 e 78.9 0.56 <0.001
Methacholine challenge 1901Discussion
In subjects with a history of bronchial hyperreactivity we
investigated the relationship between the ATS recom-
mended short five-breath dosimeter protocol1 and our own
short protocol. We demonstrated the correlation and
agreement between both methods to be significant. Data
about the use of APS in MCTs are rare and only a few studies
compare the APS to standard methods.7,8,11 Hagmolen
often Have et al.8 investigated the relationship between
SDM and APS-SC challenge in 22 children with asthma. They
found an intra class correlation (ICC) of 0.80, showing
a strong agreement. Praml and colleagues11 used the MCT
protocol of the European Community Respiratory Health
Survey (ECRHS). For a more reliable handling, they replaced
the Mefar MB3 nebuliser and adapted the protocol to the
APS. They found an overall agreement of 74% with signifi-
cantly different results for both methods (McNemar,
pZ 0.004). This was due to a larger number of PD20-posi-
tive subjects in the APS method and the variation between
the two methods was not at random.
There is a major difference in the protocols. The study in
children8 and our study used a single concentration of
39.2 mg/mL or 16 mg/mL methacholine, respectively. In theadult study,11 concentration of methacholine was switched
in the middle of the protocol from 12.5 to 66.7 mg/mL. Both
methods (PC and PD) contain a part of the other method, but
changes in concentrations and doses would influence the
outcome.
However, using a single concentration, the concentra-
tion of the starting dose will be higher. This could influence
the bronchial reaction and generate false-positive metha-
choline challenges. We saw a trend that in concentrations
above 4 mg/mL methacholine subjects tend to react more




1902 J. Schulze et al.A purpose of this study was to generate categories of BHR.
MCT is most often considered when asthma is a serious
possibility and traditional methods, most notably spirometry
performed before and after administration of a bronchodi-
lator, have not established or eliminated the diagnosis.1
Therefore, a grading system comprising BHR, borderline, and
normal limits in this clinical setting is adequate. Looking to the
future, use of MCT in asthmamay have amore prominent role
in helping in decision making about treatment, such as when
to change doses of anti-inflammatory treatment, or even stop
treatment if airway responsiveness has been normalised.12
Interestingly, there is one study13 which favours the use of
MCT as guide to long term treatment and its clinical and
histopathologic outcome. Since asthma therapy gets more
diverse, we believe that therapy monitoring with a more
distinct system of severity is helpful. However, its clinical use
has to be proven in future studies.
This is the first attempt using a standard method to
define the categories for APS-SC. Sierstedt et al.14 had
a similar approach to assess cut-points of BHR comparing
the tidal breathing method to ECRHS protocol. In this study,
each doubling PC20 cut-point was associated with
a doubling of PD20 cut-points. However, the ECRHS protocol
contains incremental dosages and concentrations. Thus, it
would be closer to the tidal breathing method. In our study,
Hahn-prognosis and Cohen’s kappa test gave major cut-off-
points with a significant agreement. Each doubling dose in
the SDM was associated with a doubling of the difference of
two consecutive doses in APS-SC (Table 3). Cut-points
revealed highest Cohen’s kappa and percent agreements,
suggesting a linear relationship between both methods.
Studies comparing different methods of bronchial chal-
lenges are not conclusive. Yan et al.15 found in histamine
provocations obtained by a hand held DeVilbiss nebuliser
not significant different values from those obtained by
a DeVilbiss 646 nebuliser. In children, Sears et al.16 showed
with a modified MCT protocol from Chai et al.17 in
comparison to a longer protocol of Hargreave et al.18 a good
agreement between the two techniques.
Although previous studies have compared both recom-
mended ATS protocols, results are not consistent. Ryan et al.19
found no difference between the methods. This was
confirmedbyWubbel et al.,4 the PC20methacholine obtained
by either method showed no significant difference.
In contrast, in the study of Cockcroft et al.6 the five-breath
dosimeter PC20 was almost twofold greater than the 2-min
tidal breathing PC20. Potential reasons for these observations
are that a double dose is administered by the tidal-breathing
method,6 and that inhalations to TLC are recognised to be
bronchoprotective, particularly in subjects with airway
responsiveness in the normal, borderline, or mild range.20
This data was confirmed by the study of Allen et al.21 The
dosimeter PC20 was larger than the tidal breathing method
and the difference was greater in subjects with mild BHR
having a PC20> 2 mg/mL. The authors suggest that subjects
with mild asthma and mild BHR behave more like normal
subjects with regard to the bronchoprotective effect of
a deep inhalation. They conclude that SDM results in
a potentially marked reduction in the sensitivity of the
challenge leading to potential for misdiagnosis.
In studies comparing SDM to APS, measurement of the
inhaled dose of methacholine (PD20) revealed differentvalues. Analysis of 18 subjects showed a small, but significant
difference in PD20.
7 In children, using a concentration of
39.2 mg/mL methacholine, PD20 for APS-SC was significantly
higher than the PD20 for SDM.
8 The difference of PD20 is
consistent with our results. However, PD20 in our trial was
lower for APS-SC than for SDM. Approximately 70% of the
aerosol produced by the DeVilbiss 646 nebuliser is within the
ideal size range (< 5 mm) for optimal delivery to the small
airways.6 The fine particle fraction (< 5 mm) of the APS neb-
uliser was on average 49.7%.11 Thus, particle size is not an
explanation for the difference in PD20. Our results for PD20 are
consistent with the data of Siersted et al.,14 showing that
cumulative dosages up to 2.9 mg methacholine lead to posi-
tive reactions. These results suggest that 16 mg/mL meth-
acholine is a suitable concentration. Higher concentrations
(e.g., 32 mg/mL) would result in a greater amount of inhaled
methacholine, lower concentrations (e.g., 8 mg/mL) would
double inhalation time and extend the test.
Without doubt the APS is a time-saving method and the
handling is easy. In the first trial, mean duration of SDM was
30.5 and of APS 16.8 min.7 Compared to our data, SDM lasted
23.4 min and APSwas similar. However, in the calculation we
included only the measurement, not the preparation of
a large number of methacholine solutions as required in the
SDM method.
In conclusion, methacholine challenge using the APS and
a short protocol is a timesaving and reliable method. A single
concentration of 16 mg/mL methacholine is a good compro-
mise between elevated concentrations and an acceptable
inhalation time. There is a close relationship between cate-
gories of BHR compared to the ATS five-breath dosimeter
method. Considering BHR, defined as provocative dose
of methacholine causing a 20% fall of FEV1, the cut-point of
8 mg/mL methacholine agrees with a dose of 1 mg meth-
acholine. These results are helpful for the daily use of APS in
research and clinical practice.
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